SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

State of the market

12-Jul-2011
Last updated on 13-Apr-2012 at 15:09 GMT

Related topics: Clinical Development

Speakers

Gareth Macdonald

Mr Gareth Macdonald

Senior Editor
Outsourcing-Pharma.com

Eric Bolesh

Mr Eric Bolesh

Cutting Edge Information
Cutting Edge Information

On average over half the cost of developing a new cancer drug is associated with work outsourced to contract research organisations (CRO), according to analysis by Cutting Edge Information. This finding, coupled with the pharmaceutical industry’s ever present desire for more efficient R&D spending, means that finding the right contractor and monitoring performance is more important than ever.

In his presentation Eric Bolesh will examine this issue and discuss the following: How pharmaceutical firms work successfully with CROs? What clinical work is contracted out to third parties? How is vendor performance measured?; and how, ultimately, is this information used to shape future sourcing strategies and drug development projects be that for a new treatment for cancer or for any other disease.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

All Webinars

Managing strategic relationships in cancer trials

Managing strategic relationships in cancer trials

The way drug companies work with CROs is evolving, with the emphasis shifting from the...

Patient recruitment: improving access to patients

Patient recruitment: improving access to patients

Recruiting patients is often, if not always, the most expensive and time consuming part of...

State of the market

State of the market

On average over half the cost of developing a new cancer drug is associated with...